Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
Cancer. 2013 Jan 1;119(1):150-7. doi: 10.1002/cncr.27707. Epub 2012 Jun 26.
The impact of race and ethnicity on the biologic features and outcome variables of women who are diagnosed with preinvasive breast cancer-ductal carcinoma in situ (DCIS)-has not been addressed widely in the published literature.
Patient demographic, clinical, and pathologic features and outcome variables were analyzed with respect to the patient's initial self-reported race/ethnicity among women who received treatment for a diagnosis of pure DCIS from 1996 to 2009.
Of 1902 patients, 1411 were white (74.2%), 214 were African American (11.3%), 175 were Hispanic (9.1%), and 102 were Asian/Pacific Islander (5.4%). The majority of patients were between ages 41 and 70 years (83%). Patients of Hispanic and Asian/Pacific Islander descent were significantly younger than white and African American patients (P < .001). DCIS size and grade, the presence of necrosis, and the frequency of breast-conserving surgery did not differ significantly between groups. African American patients aged >70 years and Hispanic patients aged <50 years were significantly more likely to have estrogen receptor-positive DCIS than patients of other races in the same age categories (P < .001). Adjuvant radiotherapy and tamoxifen were received significantly less often by white women (P < .001). At a median follow-up of 4.8 years (range, 1-14 years), recurrence rates and the development of contralateral breast cancer did not differ significantly among racial/ethnic groups when stratified by treatments received.
There was variation in age at presentation, biologic features, and treatment of DCIS among the different ethnic groups. Additional studies with larger numbers of ethnic minority patients are needed to confirm whether the consistent application of evidence-based treatment practices presents an opportunity for reducing disparities in patients with DCIS.
种族和民族对被诊断为患有乳腺导管原位癌(DCIS)的女性的生物学特征和结局变量的影响,在已发表的文献中尚未得到广泛探讨。
在 1996 年至 2009 年间,对接受单纯 DCIS 治疗的女性患者的患者人口统计学、临床和病理特征以及结局变量进行了分析,分析时考虑了患者最初自我报告的种族/民族。
在 1902 名患者中,1411 名患者为白人(74.2%),214 名患者为非裔美国人(11.3%),175 名患者为西班牙裔(9.1%),102 名患者为亚裔/太平洋岛民(5.4%)。大多数患者年龄在 41 至 70 岁之间(83%)。西班牙裔和亚裔/太平洋岛民患者明显比白人和非裔美国人患者年轻(P <.001)。各组间 DCIS 大小和分级、坏死的存在以及保乳手术的频率无显著差异。70 岁以上的非裔美国患者和<50 岁的西班牙裔患者与同年龄段的其他种族患者相比,ER 阳性 DCIS 的可能性明显更高(P <.001)。白种女性接受辅助放疗和他莫昔芬的比例明显较低(P <.001)。在中位随访 4.8 年(范围,1-14 年)期间,根据接受的治疗进行分层后,不同种族/民族组间的复发率和对侧乳腺癌的发生情况无显著差异。
不同族裔群体的发病年龄、生物学特征和 DCIS 治疗方法存在差异。需要进行更多的包含少数族裔患者的大型研究,以证实是否一致应用循证治疗实践为 DCIS 患者减少差异提供了机会。